Zenotech Laboratories Ltd (ZENOTECH) is currently trading at 40.31 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Zenotech Laboratories Limited is a Hyderabad-based pharmaceutical contract manufacturer operating as a loan-licensee, specialising in parenteral depot formulations, ophthalmic preparations, oncology oral and injectable therapies, and general injectables; it principally manufactures for and leases biotech R&D facilities to its promoter and major counterparty, Sun Pharmaceutical Industries Limited. Financially, H1 FY2026 (half year ended September 30, 2025) showed total income of Rs. 1,887.10 lakhs from operations and other operating income, with consolidated operating cash flow generation of Rs. 832.89 lakhs, driving cash and bank balances to Rs. 3,160.98 lakhs at period end and a virtually debt-free balance sheet. Profitability was materially affected by tax adjustments in the quarter: an accounting reworking under section 115BAA(5) produced an exceptional earlier-period tax adjustment of Rs. 190.49 lakhs and reversal of MAT credit and deferred tax, resulting in a modest half-year PAT of Rs. 15.30 lakhs versus Rs. 263.71 lakhs in the prior-year period. Capital deployment continued with payments for property, plant and equipment and CWIP of Rs. 423.83 lakhs during the half year, indicating selective investment in plant capacity and upgrades while the company maintains a concentrated customer relationship with Sun Pharmaceutical Industries Limited for manufacturing and leased R&D facilities. The company reports no subsidiaries under Ind AS 110 following cancellations and winding-up of overseas entities; it highlights legacy financial irregularities before November 2011 as largely settled and considers any remaining impact immaterial based on remediation steps and evidence obtained so far.

Over the past 52 weeks, Zenotech Laboratories Ltd has traded between a low of ₹33.55 and a high of ₹54.14. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Zenotech Laboratories Ltd has a market capitalization of approximately 246.01. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Zenotech Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -97.62 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 246.01 Cr, Zenotech Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Zenotech Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Zenotech Laboratories Ltd is -97.62. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Zenotech Laboratories reported a standalone net loss of ₹0.46 crore for the quarter ended June 30, 2026 (Q1FY26), based on the provided figures.